Clicky

Pulmatrix, Inc.(PULM)

Description: Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its iSPERSE technology. The company's proprietary product pipeline focuses on advancing treatments for rare diseases, including PUR1900, an inhaled anti-fungal for patients with cystic fibrosis, as well as PUR1500, an inhaled product for the treatment of idiopathic pulmonary fibrosis. It is also developing PUR0200, a branded generic in clinical development for chronic obstructive pulmonary disease and other treatments. Pulmatrix, Inc. is based in Lexington, Massachusetts.


Keywords: Medicine Organ Systems Rare Diseases Clinical Development Chronic Obstructive Pulmonary Disease Idiopathic Pulmonary Fibrosis Pulmonary Disease Cystic Fibrosis Pulmonary Fibrosis Pulmonology Treatment Of Idiopathic Pulmonary Fibrosis Interstitial Lung Disease Pulmonary Rehabilitation

Home Page: www.pulmatrix.com

PULM Technical Analysis

99 Hayden Avenue
Lexington, MA 02421
United States
Phone: 781 357 2333


Officers

Name Title
Mr. Teofilo David Raad MBA Pres, CEO & Director
Dr. Alexander M. Klibanov Ph.D. Founder
Mr. Peter Ludlum CMA, MBA Interim CFO and Principal Accounting & Financial Officer
Dr. Aidan Curran Ph.D. VP of Research & Scientific Affairs
Dr. Margaret M. Wasilewski M.D. Chief Medical Officer
Mr. David J. Maki J.D. Advisor

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.3832
Price-to-Sales TTM: 2.7564
IPO Date: 2014-03-21
Fiscal Year End: December
Full Time Employees: 24
Back to stocks